A cavity doesn’t always have to mean the dreaded sound of the dental drill, uncomfortable local anesthesia injections, or an intimidating and stressful visit to the clinic. A major clinical trial has now confirmed that a simple, inexpensive liquid can successfully stop tooth decay in young children, a breakthrough that could potentially prevent painful infections and spare thousands of kids from needing invasive dental surgery.
The treatment, known as silver diamine fluoride (SDF), takes only seconds to apply to each affected tooth. Rather than drilling away damaged tooth material and placing a traditional filling, a dentist uses a tiny sponge-tipped applicator to paint the liquid directly onto the cavity. The process requires no drilling, no injections, and no sedation, changing the fundamental experience of pediatric dental care.
The findings could have enormous implications for public health and childhood dental care systems across the country. Every year, thousands of young children in the United States visit hospital emergency departments because of severe, untreated cavities. Emergency physicians generally cannot provide the complex dental procedures needed to address the underlying problem, leaving many children with ongoing, throbbing pain and recurring infections. Other children ultimately need extensive dental surgery performed under general anesthesia, which requires them to be completely unconscious during the procedure and carries its own set of medical risks.
Now, a team of researchers led by the University of Michigan has produced compelling evidence that a much simpler, non-invasive approach can stop many cavities from getting worse and offer a safer path forward.
Major Clinical Trial Confirms Silver Diamine Fluoride Works
Published in the medical journal JAMA Pediatrics, the rigorous Phase III clinical trial included 830 children younger than 6 years old. Participants for the study were carefully recruited through community dental clinics, pediatric medical practices, and Head Start and Early Head Start programs located across Michigan, New York, and Iowa. Head Start and Early Head Start are federally supported programs that provide comprehensive early childhood education, health, nutrition, and parent involvement services to eligible low-income families.
The results of the trial showed that a clear solution containing 38% silver diamine fluoride successfully stopped decay in more than half of the affected baby teeth when the treatment was provided consistently at six-month intervals.
Dentists refer to this clinical outcome as arresting tooth decay, meaning that the damaged area stops deteriorating and the disease process is halted in its tracks. Unlike a traditional filling, the treatment does not mechanically replace lost tooth structure or rebuild the shape of the tooth. Instead, it chemically alters the environment within the lesion to prevent existing decay from progressing any further.
Silver diamine fluoride works through the combined, synergistic effects of its core chemical components: silver and fluoride. The silver component helps combat and neutralize the bacteria associated with tooth decay and infection, while the fluoride helps strengthen the remaining mineral structure of the teeth, making them far more resistant to further damage and acid erosion.
"This is a very effective and safe treatment — even in children as young as 1," said Dr. Margherita Fontana, a professor of dentistry at the University of Michigan School of Dentistry and the lead investigator of the multi-institution study.
A Simple Treatment Could Help Millions Avoid Dental Pain
Tooth decay remains the single most common chronic disease among children, affecting more than 40% of American children before they reach adolescence. Although cavities may initially cause few noticeable symptoms or discomfort, untreated decay can eventually lead to severe, debilitating toothaches, deep infections, serious problems with eating and sleeping, missed school days, and repeated, disruptive medical appointments.
For young children, conventional dental treatment can also be particularly challenging for both the patient and the practitioner. Some children are simply too young to remain still throughout a lengthy procedure, while others experience significant fear, anxiety, or behavioral management issues in a traditional dental chair.
SDF offers a practical, less traumatic alternative for many of these vulnerable patients because it can be applied quickly and quietly, entirely avoiding the heavy equipment, noise, and complex procedures required for a traditional filling.
Fontana noted that the clinical benefits could extend well beyond young children. Older adults, individuals with developmental or physical disabilities, people with severe dental anxiety, and patients who have difficulty obtaining conventional dental care due to geography, mobility, or financial constraints could also benefit tremendously from the widespread adoption of the treatment.
There is, however, one important tradeoff that patients and families must consider. Silver diamine fluoride permanently turns the decayed, vulnerable portion of a treated tooth a dark, noticeable color, which can be especially prominent on front teeth. While the discoloration is primarily cosmetic and indicates that the silver has successfully reacted with the decayed tissue, it may heavily influence whether patients and families choose the treatment for visible areas of the mouth.
For many people, however, the immediate benefit of avoiding pain, drilling, needles, or more invasive surgical procedures far outweighs that purely aesthetic drawback.
Why This Decades-Old Treatment Could Soon Reach More Patients
Silver diamine fluoride is not a newly invented substance or an untested experimental drug. Dentists have successfully and safely used it to manage and control cavities in numerous countries around the world for decades.
In the United States, the U.S. Food and Drug Administration (FDA) approved SDF as a medical device for treating tooth sensitivity back in 2014. Since that time, dentists have also used it off-label to stop cavities—meaning they apply an authorized product for a clinical purpose beyond its original approved indication.
What has been missing until now is large-scale, rigorous clinical evidence gathered from diverse U.S. populations establishing its safety and effectiveness specifically for treating active tooth decay, which represents a crucial step toward obtaining official FDA approval for that specific therapeutic use.
The University of Michigan trial was specifically designed to help fill that critical evidence gap.
"If we want more children and families to benefit from this treatment, we need rigorous evidence showing both that it works and that it’s safe. From a public health perspective, if we want broader implementation across the United States, including in medical settings, we need carefully collected data in U.S. populations, and we now have that," Fontana said.
The clinical investigation officially began in 2018 and persevered through the unprecedented disruptions, logistical challenges, and safety protocols caused by the COVID-19 pandemic.
The researchers believe that having stronger, high-quality clinical evidence could make SDF much more widely available, including in pediatric medical settings where young children often receive routine healthcare years before their very first dental appointment.
"In medicine, clinicians want high-quality evidence before changing practice," Fontana said. "It is important to have data they can refer to because young children often see pediatricians years before they ever visit a dentist. Broader acceptance could allow many more cavities to be treated while a referral to a dental home is successful, and before they become painful, infected or require surgery."
A dental home refers to an ongoing, continuous relationship between a patient and a dental care provider who can deliver comprehensive preventive care, timely treatment, and necessary follow-up services over the years.
Expanding clinical access to SDF could allow more children to receive early intervention before relatively manageable cavities develop into severe, complicated dental emergencies.
FDA Approval Could Expand Access to Cavity Treatment
The landmark trial brought together a collaborative team of researchers from the University of Michigan, New York University, the University of Iowa, and Indiana University. Financial backing for the study was robust, with the National Institute of Dental and Craniofacial Research, a division of the National Institutes of Health, providing more than $12 million in grant funding.
The commercial product tested during the trial was Advantage Arrest 38% SDF, which was supplied by the manufacturer Elevate Oral Care.
The comprehensive findings provide solid clinical trial data that the manufacturer and other stakeholders can utilize in a formal application seeking FDA approval of SDF as an official drug for arresting dental caries, the formal medical term for tooth decay.
Dr. Amr Moursi, a professor of pediatric dentistry at the New York University College of Dentistry and a co-principal investigator on the study, emphasized the potential importance of that regulatory change for the broader dental community.
"Our results support FDA approval of SDF for managing arrest of tooth decay in young children. Removing SDF from off-label status would be an important innovation which could lead to increased utilization by providers, enhanced payments by insurers and more consistent product quality," Moursi said.
For many young children, receiving another routine application of silver diamine fluoride every few months could be entirely sufficient to keep a cavity under control and stable until the affected baby tooth naturally falls out to make room for permanent teeth.
Adults could also benefit from the approach, either by using SDF to manage chronic decay over a longer period or as a safe temporary solution until a permanent filling or another restorative procedure becomes financially or practically feasible.
While the treatment is certainly not suitable for every single cavity, and stopping ongoing decay does not necessarily eliminate the underlying need for future dental maintenance, the findings suggest that a simple procedure requiring only seconds to perform could help a vast number of patients avoid much more complicated and painful treatment.
"For almost anyone, this can arrest the decay and stop the infection and the pain it causes," Fontana said. "This could benefit many people."
